Advertisement
CPRX vs VIR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPRX is a Hold and VIR is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CPRX’s FA Score shows that 2 FA rating(s) are green whileVIR’s FA Score has 1 green FA rating(s).
- CPRX’s FA Score: 2 green, 3 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CPRX’s TA Score shows that 2 TA indicator(s) are bullish while VIR’s TA Score has 4 bullish TA indicator(s).
- CPRX’s TA Score: 2 bullish, 4 bearish.
- VIR’s TA Score: 4 bullish, 6 bearish.
Price Growth
CPRX (@Biotechnology) experienced а -0.06% price change this week, while VIR (@Biotechnology) price change was -2.99% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.
Reported Earning Dates
CPRX is expected to report earnings on Aug 12, 2026.
VIR is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (-3.21% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CPRX | VIR | CPRX / VIR | |
| Capitalization | 3.85B | 1.64B | 235% |
| EBITDA | 306M | -460.62M | -66% |
| Gain YTD | 34.876 | 61.194 | 57% |
| P/E Ratio | 18.20 | N/A | - |
| Revenue | 597M | 64.7M | 923% |
| Total Cash | 756M | 476M | 159% |
| Total Debt | 2.68M | 95.6M | 3% |
CPRX | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 56 Fair valued | |
PROFIT vs RISK RATING 1..100 | 14 | 100 | |
SMR RATING 1..100 | 39 | 99 | |
PRICE GROWTH RATING 1..100 | 41 | 38 | |
P/E GROWTH RATING 1..100 | 26 | 31 | |
SEASONALITY SCORE 1..100 | 23 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (56) in the null industry is in the same range as CPRX (72) in the Pharmaceuticals Other industry. This means that VIR’s stock grew similarly to CPRX’s over the last 12 months.
CPRX's Profit vs Risk Rating (14) in the Pharmaceuticals Other industry is significantly better than the same rating for VIR (100) in the null industry. This means that CPRX’s stock grew significantly faster than VIR’s over the last 12 months.
CPRX's SMR Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for VIR (99) in the null industry. This means that CPRX’s stock grew somewhat faster than VIR’s over the last 12 months.
VIR's Price Growth Rating (38) in the null industry is in the same range as CPRX (41) in the Pharmaceuticals Other industry. This means that VIR’s stock grew similarly to CPRX’s over the last 12 months.
CPRX's P/E Growth Rating (26) in the Pharmaceuticals Other industry is in the same range as VIR (31) in the null industry. This means that CPRX’s stock grew similarly to VIR’s over the last 12 months.
| CPRX | VIR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 83% |
| MACD ODDS (%) | N/A | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 81% |
| Advances ODDS (%) | 12 days ago 77% | 21 days ago 74% |
| Declines ODDS (%) | N/A | 1 day ago 81% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 73% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MNZL | 61.15 | N/A | N/A |
| Manzil Russell Halal USA Broad MarketETF | |||
| RFM | 14.91 | -0.03 | -0.20% |
| RiverNorth Flexible Municipal Income Fund | |||
| FIGB | 42.46 | -0.15 | -0.35% |
| Fidelity Investment Grade Bd ETF | |||
| BBAX | 61.08 | -0.33 | -0.54% |
| JPMorgan BetaBuilders Dev APAC ex-JpnETF | |||
| RSSY | 25.33 | -0.18 | -0.71% |
| Return Stacked U.S. Stocks & Futures Yield ETF | |||
CPRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with TRDA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then TRDA could also see price increases.
| Ticker / NAME | Correlation To CPRX | 1D Price Change % | ||
|---|---|---|---|---|
| CPRX | 100% | +0.03% | ||
| TRDA - CPRX | 39% Loosely correlated | -4.62% | ||
| PCVX - CPRX | 38% Loosely correlated | -2.03% | ||
| SANA - CPRX | 37% Loosely correlated | -5.45% | ||
| VIR - CPRX | 36% Loosely correlated | -2.41% | ||
| XNCR - CPRX | 36% Loosely correlated | -5.62% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -2.41% | ||
| BEAM - VIR | 54% Loosely correlated | -5.14% | ||
| PCVX - VIR | 52% Loosely correlated | -2.03% | ||
| DNLI - VIR | 51% Loosely correlated | +3.12% | ||
| RCUS - VIR | 50% Loosely correlated | -2.94% | ||
| XNCR - VIR | 50% Loosely correlated | -5.62% | ||
More | ||||